MedTrace Logo

Risk of CKD in Diabetic Patients With MAFLD

NCT06304844 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2024-03-18

No results posted yet for this study

Summary

This cross-sectional study of 300 participants investigates the risk of chronic kidney disease (CKD) in individuals with metabolic dysfunction-associated fatty liver disease (MAFLD) and type 2 diabetes. By evaluating hepatic measurements and metabolic markers, the study aims to identify key risk factors for CKD in this population, contributing valuable insights to inform targeted interventions.

Conditions

Interventions

DIAGNOSTIC_TEST

transient elastography (Fibroscan)

conduct fibroscan for patients with (MAFLD by abdominal ultrasonography)

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-20
Primary Completion
2024-10-01
Completion
2025-02-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06304844 on ClinicalTrials.gov